Vantage Consulting Group’s Bio-Techne TECH Stock Holding History

Vantage Consulting Group’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-132	Closed	-$10K	–	1410
2020 Q4	$10K	Buy	+132	New	+$9.56K	﹤0.01%	1212

Other funds holding TECH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DDC

DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return

Vantage Consulting Group's TECH Position: Q1 2021 in Review

Vantage Consulting Group sold out of Bio-Techne (TECH) in Q1 2021, closing a stake of 132 shares — an estimated $10K sold.

Vantage Consulting Group first reported a position in TECH in Q4 2020 and held it in 1 quarter. The position peaked at $10K in Q4 2020. 470 funds tracked by Wall St. Rank hold TECH as of Q1 2021.

Vantage Consulting Group reported no remaining Bio-Techne position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 132 Bio-Techne shares in Q1 2021, an estimated $10K.
Vantage Consulting Group first reported a position in Bio-Techne in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's Bio-Techne position peaked at $10K in Q4 2020.
470 funds tracked by Wall St. Rank held Bio-Techne as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.